Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker

Proteins secreted from specific cancer cells have a high potential for use as tumor markers. We identified secreted proteins produced by 15 different carcinoma cell lines grown in serum‐free medium using MS/MS. Proneurotensin/neuromedin N (proNT/NMN) was found in conditioned medium from four of seven small cell lung carcinoma cell lines but not from eight nonsmall cell lung carcinoma cell lines. These results indicate proNT/NMN has potential as a specific tumor marker of small cell lung carcinoma.

[1]  R. Dwek,et al.  Proteome analysis of a human uveal melanoma primary cell culture by 2‐DE and MS , 2005, Proteomics.

[2]  Tomoko Umaki,et al.  Possible detection of pancreatic cancer by plasma protein profiling. , 2005, Cancer research.

[3]  J. Carmody,et al.  Mass profiling‐directed isolation and identification of a stage‐specific serologic protein biomarker of advanced prostate cancer , 2005, Proteomics.

[4]  T. Colgan,et al.  A strategy for high‐resolution protein identification in surface‐enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma , 2005, Proteomics.

[5]  T. Colgan,et al.  Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. , 2005, Journal of proteome research.

[6]  G. Bepler,et al.  Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. , 2004, Lung cancer.

[7]  D. Dillon,et al.  2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474. , 2004, Journal of proteome research.

[8]  Donald R Schwartz,et al.  Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: A strategy for identification of candidate cancer biomarkers , 2004, Proteomics.

[9]  F. Miller,et al.  A two‐dimensional liquid‐phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification , 2004, Proteomics.

[10]  Yu Shyr,et al.  Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.

[11]  Michael J Campa,et al.  Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. , 2003, Cancer research.

[12]  M. Oka,et al.  Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. , 2002, Cancer research.

[13]  P. Kitabgi,et al.  Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity. , 2002, Biochemical and biophysical research communications.

[14]  Y. Akiyama,et al.  Mass spectrometric high-throughput analysis of serum-free conditioned medium from cancer cell lines. , 2001, Cancer letters.

[15]  J. Laissue,et al.  Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas , 1999, International journal of cancer.

[16]  H. Dienemann,et al.  Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. , 1999, Anticancer research.

[17]  R. Carraway,et al.  Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations , 1997, The Prostate.

[18]  B. Evers,et al.  Inhibition of neurotensin‐induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692 , 1997, Cancer.

[19]  R. Kiss,et al.  Neurotensin-mediated effects on astrocytic tumor cell proliferation , 1996, Neuropeptides.

[20]  E. Daniel,et al.  Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum , 1994, British journal of pharmacology.

[21]  K. Yamaguchi,et al.  Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. , 1994, Cancer research.

[22]  T. Davis,et al.  Neurotensin may function as a regulatory peptide in small cell lung cancer , 1991, Peptides.

[23]  S. McNeil,et al.  The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences. , 1988, The Journal of biological chemistry.

[24]  F. Checler,et al.  Neuromedin N: high affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases. , 1986, European journal of pharmacology.

[25]  P. Kitabgi,et al.  Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. , 1986, Molecular pharmacology.

[26]  J. Fahrenkrug,et al.  Neurotensin-like immunoreactivities in human plasma: Feeding responses and metabolism , 1986, Peptides.

[27]  C. Pert,et al.  High levels of intracellular bombesin characterize human small-cell lung carcinoma. , 1981, Science.

[28]  Gabriela Alexe,et al.  A robust meta‐classification strategy for cancer detection from MS data , 2006, Proteomics.

[29]  John D. Minna,et al.  Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.